Thromboxane (TXA2) activates the T prostanoid (TP) receptor. Prostaglandin E2 (PGE2) activates four E prostanoid (EP) receptors, EP1-4. AH-23848 is a dual antagonist of TP1 and EP4 receptors.2 It originally was found to inhibit TXA2-induced platelet aggregation (IC50 = 0.26 μM)1 and the contraction of human bronchial smooth muscle induced by the TP agonist U-46619.3 AH-23848 was subsequently demonstrated to impair PGE2-mediated relaxation of piglet saphenous vein by antagonizing the PGE2 receptor EP4.2 By inhibiting EP4, it likewise suppresses serum-induced cAMP generation, cyclin A synthesis, and the proliferation of fibroblasts4, as well as reduces metastasis in a mouse model of metastatic breast cancer.5
≥90%
参考图片
本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.iamyjet.com/article/13687.html